埃克替尼用于治疗肺腺癌脑转移的效果及影响因素分析

The Effect and Influential Factors of Icotinib on Brain Metastases from Lung Adenocarcinoma

目的:探讨埃克替尼在肺腺癌脑转移治疗中的效果,并进一步分析影响疗效的相关因素。方法:回顾性分析32例肺腺癌脑转移患者的临床资料,所有患者均口服埃克替尼125 mg/次,3次/d,直到疾病进展或发生不可耐受的毒副反应。结果:32例患者颅内病灶的有效率(RR)56.25%,疾病控制率(DCR)90.63%,颅外病灶的RR 43.75%,DCR 87.50%。中位疾病进展时间8.23个月,不同脑转移灶数目比较差异有统计学意义(P<0.05);中位总生存19.14个月,不同KPS评分、脑转移灶数目差异有统计学意义(P<0.05)。本组患者的1年生存率68.8%,主要不良反应为皮疹、腹泻,多为1~2级。结论:埃克替尼治疗肺腺癌脑转移疗效好,不良反应可耐受,值得临床推广。

Objective：To investigate the effect of Icotinib in the treatment of brain metastases from lung adenocarcinoma and to find out the effectrelated factors.Method：Thirty-two lung adenocarcinoma patients with brain metastases were reviewed retrospectively.All these patients were treated with Icotinib administered orally （125 mg,3 times a day） until disease progression or unacceptable toxicities.Result：In terms of intracranial lesions,the response rate（RR） and disease control rate（DCR） were 56.25% and 90.63%.AS for systemic disease,RR and DCR were 43.75% and 87.50%.The median time to disease progression was 8.23 months,which related to the number of brain metastases,while the median survival time was 19.14 months,which was related to the patients＇ KPS score and the number of brain metastases.One year survival rate was 68.8%.Rash and diarrhea,mainly in grade 1-2,were the most common side effects of Icotinib.Conclusion：Icotinib is effective and tolerable in patients with brain metastases from lung adenocarcinoma.